

Nutrition in Clinical Practice

A national evaluation of harm associated with patient safety incident reports related to the provision of parenteral nutrition to patients using a national incident reporting system

Journal:	<i>Nutrition in Clinical Practice</i>
Manuscript ID	NCP-2022-12-444.R1
Manuscript Type:	Clinical Observations
Keywords:	incident report, medication error, Parenteral nutrition < Nutrition, patient safety incidents
Abstract:	<p>Background Parenteral nutrition (PN)-related patient safety incidents have been associated with harm. Large scale studies are scarce and little is known about contributory factors. This study evaluated PN-related incident reports that described harm using a national database.</p> <p>Materials and Methods A retrospective evaluation of incident reports involving PN in England and Wales, reported to the National Reporting and Learning System (NRLS) between April 2015-March 2020. Quantitative analysis was used to describe frequency by degree of reported harm and incident characteristics. Content analysis was undertaken to understand contributory factors for reports related to moderate/severe harm, or death.</p> <p>Results 12,907 incident reports were identified. After screening 2242 were evaluated; 1879 (83.8%) reported no harm, 309 (13.8%) low harm, 47 (0.02%) moderate harm, 4 (0.002%) severe harm, 3 (0.001%) deaths. Most reported age group, medication process and error category was neonates (<28 days) (n=570/1923, 29.6%), administration (n=1126/2242, 50%), and omitted medication/ingredient (n=291/2242, 13%), respectively. Content analysis of reports related to moderate/severe harm and death revealed patient age <1 year, dependence on home parenteral nutrition (HPN), co-morbidities and staff mistakes as contributory factors.</p> <p>Conclusions This is the first evaluation of PN-related incident reports in England and Wales to our knowledge. We demonstrated a low frequency of reports related to moderate or severe harm or death. More incidents were reported for neonates and during the administration processes. To reduce harm, systems/procedures that reduce errors in high-risk patients (e.g., neonates, HPN patients) need to be established within organizations. Database limitations of voluntary reporting systems were recognized.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1 Manuscript

2 Abstract

3 Background

4 Parenteral nutrition (PN)-related patient safety incidents have been associated with harm. Large scale studies
5 are scarce and little is known about contributory factors. This study evaluated PN-related incident reports
6 that described harm using a national database.

7 Materials and Methods

8 A retrospective evaluation of incident reports involving PN in "Country Y" and "Country Z", reported to the
9 "database name removed" between April 2015-March 2020. Quantitative analysis was used to describe
10 frequency by degree of reported harm and incident characteristics. Content analysis was undertaken to
11 understand contributory factors for reports related to moderate/severe harm, or death.

12 Results

13 12,907 incident reports were identified. After screening 2242 were evaluated; 1879 (83.8%) reported no
14 harm, 309 (13.8%) low harm, 47 (0.02%) moderate harm, 4 (0.002%) severe harm, 3 (0.001%) deaths. Most
15 reported age group, medication process and error category was neonates (<28 days) (n=570/1923, 29.6%),
16 administration (n=1126/2242, 50%), and omitted medication/ingredient (n=291/2242, 13%), respectively.
17 Content analysis of reports related to moderate/severe harm and death revealed patient age <1 year,
18 dependence on home parenteral nutrition (HPN), co-morbidities and staff mistakes as contributory factors.

19 Conclusions

20 This is the first evaluation of PN-related incident reports in "Country Y" and "Country Z" to our knowledge.
21 We demonstrated a low frequency of reports related to moderate or severe harm or death. More incidents
22 were reported for neonates and during the administration processes. To reduce harm, systems/procedures
23 that reduce errors in high-risk patients (e.g., neonates, HPN patients) need to be established within
24 organizations. Database limitations of voluntary reporting systems were recognized.

1 **Abbreviations**

- 2
- 3 2 GDPR General Data Protection Regulation; HPN Home parenteral nutrition; HRA Health Research Authority;
- 4
- 5 3 ILE Lipid injectable emulsion; NCC MERP National Coordinating Council for Medication Error Reporting and
- 6
- 7 4 Prevention; "organization removed"; "database name removed"; PN Parenteral nutrition; WHO World
- 8
- 9
- 10 5 Health Organization
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For Peer Review

1. Introduction

Parenteral nutrition (PN) is a multi-ingredient medicinal product administered intravenously when nutritional requirements cannot be met using the gastro-intestinal tract. It contains macro and micronutrients needed to sustain life, comprising of over 40 ingredients. This complexity raises concerns about physicochemical stability. It can be used short term in hospital, but also be given as home parenteral nutrition (HPN) for long term conditions. Indications for PN include inadequate or unsafe oral/enteral nutrition, or due to a non-functioning, inaccessible or perforated gastro-intestinal tract.¹

PN is widely regarded, but not unanimously, as a high-risk medicine.^{2,3} Its speciality use may contribute to lack of familiarity with products and procedures among healthcare professionals who does not use PN in their daily practice. The World Health Organization (WHO) do not recognise PN as a high-risk medicine,⁴ however in the USA PN is broadly accepted as a high-risk medicine in acute care.⁵⁻⁷ Prescribing, compounding and administration errors related to PN are believed to be multifactorial, related to lack of training and human error.⁸ A “patient safety incident” is defined by the “organization removed” in “Country Y” and “Country Z” as any unintended or unexpected incident which could have, or did lead to harm.⁹ In “Country Y” and “Country Z”, the “database name removed” is the national repository for patient safety incident reporting data used by the “organization removed”.

A recent review of the literature suggest PN-related incidents occur during any part of the medication process and in all patient age groups, although children may be more susceptible to harmful outcomes.¹⁰ Incident types were divided into the following categories; microbial contamination,¹¹⁻¹⁴ venous access incidents involving extravasation,¹⁵⁻¹⁹ incidents related to specific PN-components or the compounded bag.²⁰⁻²² Lipid injectable emulsion (ILE), glucose, electrolytes and micronutrients components of PN have been involved in case reports.²³⁻²⁸

A national review of PN-related incidents in the USA reported over two years, in all age groups was published in 2017.²⁹ There were 1311 incidents, of which 19 (1.4%) caused harm. ILE was the most frequently occurring PN component associated with reported incidents (257/1311, 20%). The most common medication process was administration (497/1311, 38 %), the most common error type, was improper dose/quantity (541/1311, 41%). Incidents were not sub-divided into patient age groups. This study suggested a low incidence of harmful

1 events associated with PN. Other prevalence studies also showed a low incidence of harm, although were
2 either focussed on a specific age group, were local studies or not focussed exclusively on PN.³⁰⁻³² Large scale
3 studies are scarce, and there is little understanding of contributory factors associated with harmful events.
4
5 The “database name removed”, like other incident reporting systems, include headings where free text
6 descriptions of what happened, actions preventing reoccurrence and apparent causes can be added by the
7 reporter. Analyzing the information reported in these sections can support learning and developing
8 interventions based on findings to reduce/eliminate future events.

9
10 The aim of this study was to evaluate PN-related patient safety incident reports related to harm in “Country
11 Y” and “Country Z” using a national database. The objectives were, (1) to evaluate PN-related incident reports
12 by category; patient age group, location, speciality, medication process and medication error category, (2) to
13 assess relationships between reported categories, and (3) to qualitatively analyze free-text description for
14 PN-related incident reports that were related to moderate/severe harm or death, to provide an insight into
15 contributing factors.

16 **2. Methods**

17 **2.1. Design**

18 This retrospective cross-sectional study was an evaluation of medication incident reports involving PN
19 reported to the “database name removed”, the national incident reporting system in “Country Y” and
20 “Country Z”. Qualitative analysis using content analysis was conducted on incident reports that were
21 categorized as moderate/severe harm or death. The primary outcome was the assessment of harmful
22 incident reports related to PN to understand the level of harm associated with these incident reports.
23 Secondary outcome measures to enable further detailed evaluations included the following categories;
24 patient age, location, speciality, care setting, medication process, medication error category, staff reporter
25 type.

26 **2.2. Data extraction**

27 Data extraction required approval by the “database name removed” and careful consideration to capture all
28 relevant incidences. Relevant incident reports occurring between April 2015 and March 2020 were retrieved
29 by the “database name removed”. This 5-year period was selected to capture an accurate reflection of
30 current incidents, excluding incidents related to outdated practices.

1 Formulation of the final search criteria involved an iterative process between the primary investigator (PM)
2 and the “database name removed” data analyst team to obtain a dataset of relevant incident reports. Full
3 details of the agreed search terms and sampling are included as supplementary material. Broad name and
4 brand name search terms were agreed upon with the “database name removed” data analyst team. A
5 database search of the broad names and brand names was carried out by the “database name removed”
6 data analyst team. All entries were supplied for analysis. A database search of the broad names or brand
7 names was also conducted. For these entries all incident reports resulting in moderate/severe harm or death
8 were provided, and a random sample of incident reports resulting in low (23.1%) or no (16.8%) harm. The
9 search was confined to patient safety incident reports related to PN reported under the NLRS medication
10 incident category. Patients of all age groups and all care settings were included. Incident reports of all degrees
11 of harm and all medication processes were included in the analysis.

12 **2.3. Data analysis**

13 Irrelevant entries were identified by the primary investigator using the approved drug name field to highlight
14 incident reports caused by other drugs, and then removed if not related to PN. Any incident reports with
15 incomplete approved drug name entries were manually checked. During analysis, coding discrepancies were
16 noted by the primary investigator, although no entries were changed. IBM® SPSS® Statistics (version 26) was
17 used for quantitative analysis. Full details of the fields used in the analysis are included as supplementary
18 material.

19 Descriptive statistics were used to describe patient demographic data. Statistical analysis was not
20 appropriate for this observational data. Data for adults (≥ 18 years) and children (0-17 years) were combined
21 to enable comparison for medication process and degrees of harm.

22 Content analysis of free-text data in incident reports related to moderate/severe harm or death was
23 performed to uncover meaningful patterns.³³ The free-text data within the “database name removed” fields
24 for descriptions of what happened, actions preventing reoccurrence and apparent causes were read as a
25 whole and analyzed to form themes relating to incident types, contributory factors and outcomes. This
26 initially involved formation of codes from the free-text. Codes can be described as a word or short phrase
27 that symbolically assigns a summative, salient, essence-capturing, and/or evocative attribute for a portion
28 data.³⁴ Codes were then grouped to form *themes* to express underlying meanings within the text.³⁵ During

1 content analysis incident reports not related to PN, were removed from the analysis. They were not removed
2 from all analysis as this level of scrutiny was not applied to those reported as no/low harm.

3 **2.4. Ethical considerations**

4 Ethical approval by the "XXXXXX Institution", "Ethics committee removed" (XXXXX: 60567) for a service
5 evaluation was obtained for this Master's study. Approval for this service evaluation was also obtained from
6 "the Hospital" (SEV/0299). "National Ethics committee name removed" approval was not required. Data files
7 extracted from the "database name removed" database were password protected and accessed only from
8 the protected hospital server to ensure secure data storage. The data retrieved from "database name
9 removed" were anonymous however "national regulation name removed" was followed in line with
10 "database name removed" requirements.³⁶

11 **3. Results**

12 The search of selected PN terms identified 12,907 incident reports between April 2015 and March 2020, of
13 which 2339 incident reports were supplied by the "database name removed" team. All incident reports
14 related to moderate and severe harm or death were provided. For incident reports related to low or no harm,
15 a sample was provided with consideration to feasibility for a master's project. After screening, 2242 reports
16 were included in this evaluation (Figure 1). There were 354 reports with blank fields for *approved drug name*
17 or an entry such as "?" or "-". These were manually checked and 14 reports were removed. Seventeen
18 duplicate reports with the same incident number were also removed.

19 Of the 2242 incident reports, there were 1879 incident reports that had been reported to have caused no
20 harm, 309 low harm, 47 moderate harm, 4 severe harm and 3 deaths.

21 **3.1. Characteristics of incident reports**

22 The highest number of incident reports involved neonates (<28 days) (n=570/1923, 30%), followed by
23 children between 1 month and 1 years old (n=397/1923, 21%) (Figure 2).

24 Table 1 shows the breakdown of incident reports by degree of reported harm and patient age group, location
25 and speciality. All incident reports occurred within an acute/general hospital care setting. Four incident
26 reports were reported to have occurred in community hospitals, however this was found to be a reporter
27 error. The location for the majority of the incident reports were within in-patient ward areas (n=1780/2236,

1 79.6%), followed by support services (n=264/2236, 29%), within which 96% (n=254/264) were reported in
2 pharmacy. Medical specialities were the most reported speciality group (n=743/2242, 33%). Subheadings
3 under this speciality included gastroenterology, nephrology, neurology, respiratory, oncology, general
4 medicine and neonatology. Neonatology was also listed as a subheading under children's specialities, hence
5 variations in reporting specialities were noted. Several inconsistencies were noted when reviewing the data
6 e.g., 1198 incident reports were in children aged under 18 years, yet only 210 reported under children's
7 speciality, suggesting reporter differences when assigning locations and/or specialities. Incident reports were
8 also categorized by medication process and medication error category (Table 2). For medication process the
9 highest number of incident reports were described as administration/preparation in clinical area
10 (n=1126/2242, 50%), and was also the most frequent across all reported degrees of harm. There were seven
11 incident reports under supply or use of OTC medicines category. PN is a prescription only medicine in the
12 "Country X", therefore these were likely reporter errors. The most reported medication error category was
13 omitted medication/ingredient (n=291/2242, 13%).

14 **3.1. Patient age groups and degree of reported harm**

15 The number of reported moderate/severe harm and deaths in the adult and children age groups were similar.
16 In children there were 25 incident reports, of which two were related to severe harm, and two deaths. In
17 adults there were 23 serious incident reports, of which one was related to severe harm and one death.

18 **3.2. Patient age and medication process**

19 The proportion of incident reports within administration/preparation in clinical area were similar (52%) for
20 children and adults (Table 3). Children had a higher proportion of prescribing incident reports than adults
21 (15% and 11% respectively), although adults had a higher proportion of incident reports within preparation
22 from all locations/dispensing from pharmacy than children (25% and 18% respectively).

23 **3.3. Medication error categories within medication process**

24 For most error categories, administration/preparation in clinical area was the most frequently reported
25 process (Table 4). The most frequently reported error category was omitted medication/ingredient within
26 administration/preparation in clinical area (n=142/291, 49%) and preparation from all locations/dispensing

1 from pharmacy process (n=96/493, 19%). For prescribing the most frequently reported error category was
2 wrong/unclear dose or strength (n=67/305, 22%).
3

4 **3.4. Staff reporter type**

5 Staff reporter type was only reported in 0.94% (n=21/2242) of incident reports and left blank in the rest. Staff
6 nurses/midwives/health visitors reported most of these incident reports (n=13/21, 62%).
7

8 **3.5. Content analysis**

9 There were 54 incident reports related to moderate/severe harm or death. On closer inspection, it was
10 discovered that one was not a PN incident and therefore excluded from content analysis.
11

12 There were eight overarching themes which described the incident reports (Table 5). The most common was
13 administering medicines. In addition to PN, insulin, glucose and electrolyte solutions were also cited as being
14 involved. The most frequent incident type within this theme was adverse events from administration, which
15 was related to extravasation of PN in all cases.
16

17 Patient factors were the most frequently occurring contributory factor theme (Table 6). The majority of these
18 were patient dependent on HPN. HPN patients were often also patients with co-morbidities. In addition to
19 nutrients, they would require strict fluid and electrolyte management, and missed infusions were reported
20 to have severe consequences of acute kidney injury, deranged blood glucose control and hypokalaemia. Most
21 HPN incident reports were related to dispensing or supply of infusions. Being at home without access to
22 immediate medical intervention could make these patients more vulnerable if infusions are missed. PN
23 extravasation was the most frequent incident reported in children less than 1 year, and over half of these
24 were neonates. Organization was the second most frequently occurring theme. The most frequent factor
25 within this theme was service failure of an external company due to a national incident and affected HPN
26 patients. Staff factors were the third most common theme, with mistakes being the most frequent
27 contributory factor. The majority of these were administration incident reports. The fourth theme was
28 equipment and venous access devices used to infuse PN was a common contributory factor.
29

30 Themes relating to patient outcomes are displayed in Figure 3. Patient harm included clinical outcomes such
31 as pathophysiological/disease related, patient injury or patient death. Pathophysiological/disease related
32 outcomes included fluid/electrolyte disturbances and blood glucose control. All reported outcomes were PN
33

1 extravasation. There were three incidents reported as death, two of which involved HPN patients, one
2 contributed to delivery failure in an adult patient and one was a compounding incident in a child aged 12-17
3 years. The third death was contributed to by an overdose of PN due to a mistake in infusion rate in a neonate.
4 The non-clinical outcomes described inconvenience to patients but are also a burden on healthcare
5 organizations, through repeated tests/procedures or additional treatment and unplanned hospital
6 admissions which were reported.

7 **4. Discussion**

8 **4.1. Main findings**

9 To our knowledge, this is the first national evaluation focussed on PN incident reports across all patient ages
10 in "Country Y" and "Country Z". The "database name removed" database search of PN terms returned 12,907
11 incident reports over a 5-year period, of which only 54 reported moderate/severe harm or death. Although
12 this represents raw data before screening, only 0.4% of incident reports were related to moderate/severe
13 harm or death. The dataset of 2242 incident reports included a sample of no/low harm incident reports and
14 all incident reports of moderate/severe harm or death. On examination, only 53 incident reports were related
15 to moderate/severe harm or death. Snijders et al.³⁰ and Storey et al.²⁹ reported that 1% (n=3/304) and 1.4%
16 (n=19/1311) of PN-related incidents respectively, caused significant harm. Both studies used national
17 reporting databases, although Snijders et al. [28] looked only at incidents in neonatal intensive care units.
18 Local observational studies by Narula et al.³² and Sacks et al.³¹ reported that 6% (n=3/46) and 8% (n=6/74)
19 of PN-related incidents respectively, caused significant harm. Narula et al. [30] reported data in a pediatric
20 centre, and Sacks et al. [29] reported incidents in all age groups. In comparison, the "database name
21 removed" data revealed a large number of incident reports involving PN. The prevalence and populations
22 cannot be compared, however our study demonstrated a lower proportion of incident reports related to
23 moderate/severe harm or death than the studies mentioned above. This higher proportion could be related
24 to differences in reporting to national and local databases, or assigning degree of harm. Snijders et al.³⁰ used
25 a similar approach to the "database name removed" to describe degrees of harm, ranging from no harm to
26 death, where significant harm was described as moderate/severe or death. The other three studies used the
27 National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) index to assign

1 harm to incidents.³⁷ This index uses 9 categories (A to I) to describe levels of harm, and significant harm in
2 these studies were incidents categorized grades E to I (temporary harm to death).

3
4
5
6 3 Overall, 62% of incident reports were in children, with incident reports in neonates occurring most
7 frequently. Infants under 1 year were also highlighted as a commonly occurring contributory factor in
8 incident reports of moderate/severe harm or death. This could be due to complexity of weight-based dosing
9 or vulnerability due to the under-developed defence mechanisms and developing organs.^{38,39} Within the
10 adult group, most incident reports were reported in the 66-75 years age group. This requires further
11 investigation and may be related to a combination of factors such as co-morbidities and volume of PN used
12 in this patient population, e.g., post-operative surgical complications requiring short-term PN or eligibility for
13 HPN. There were a similar number of incident reports of moderate/severe harm or death between adults
14 and children for the sample of incident reports we analyzed. This was based on the assumption that this
15 sample was representative of the whole dataset of incidents. This differs from published literature which
16 suggests children are more susceptible to harm than adults from medication errors.^{38,39} This may be related
17 to the multifactorial nature of contributory factors found in this evaluation, such as the influence of a national
18 HPN incident.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 16 The single most common medication process reported for both adults and children, and for all reported
37 degrees of harm was administration. This was in agreement with the study by Storey et al.,^{29,39} and several
38 published case studies.^{16-18,24,27,28} In the "Country X" it is recommended that additions to PN bags, including
39 multi-chamber bags, only occur in the pharmacy aseptic unit.⁴⁰ This may vary in other parts of the world, and
40 studies have described the supplementation of micronutrient and/or electrolyte to multi-chamber bags in a
41 clinical setting.⁴¹⁻⁴³ This difference in practice should be considered when comparing incident rates in other
42 countries. Extravasation injuries, patient age less than one year and venous access devices were predominant
43 factors for administration incident reports of moderate/severe harm or death. These incident reports were
44 found to be the result of insufficient monitoring or inappropriate venous access devices, e.g., peripheral
45 intravenous route used for high osmolarity PN that should only be infused centrally. Extravasation injuries in
46 infants due to PN has been recognised in several case reports, and has also been highlighted by this study.
47
48
49
50
51
52
53
54
55
56
57
58
59
60 27 ¹⁵⁻¹⁸ Incident reports related to the wrong dose being administered were frequently related to a mistake
28 being made by healthcare staff, although were difficult to categorize further due insufficient information.

1 The proportion of incident reports that had occurred during the administration process in children was similar
2 to adults. The higher proportion of incident reports for children in the prescribing process may be related to
3 the complexity of PN prescribing in children.³⁹ The higher proportion of incident reports for adults within
4 dispensing process was in agreement with the results by Bateman et al.⁴⁴ Further investigation of
5 contributory factors focussing on dispensing incidents is required.

6 Age under one year was identified as a contributing factor together with venous access devices and mistakes.
7 The added complexity of separate ILE and non-lipid PN infusions creates an area for potential errors in these
8 patients. Further development of all-in-one PN products for this age group could remove the need for
9 separate ILE and non-lipid PN infusions. PN when used in neonates and infants under one year should be
10 treated as a high-risk medication, accompanied with double-checking procedures during set-up and the
11 infusion period. Stringent venous access protocols that comply with national guidance for neonates may also
12 reduce PN extravasation injuries.⁴⁵

13 The top five medication error categories were, omitted medication, wrong quantity, wrong dose, wrong
14 medicine and wrong frequency. Content analysis of the incident reports described as moderate/severe harm
15 or death found that administration incidents involving PN were often related to the wrong rate. *Rate* is not
16 specifically listed as a medication error category option within the "database name removed" leaving
17 reporters having to decide between wrong dose, quantity, strength or frequency. Cross-tabulation between
18 medication process and medication error category showed for both administration and dispensing, omitted
19 medication was the highest reported error category. In comparison, Storey et al.,²⁹ reported improper
20 dose/quantity as the most common error in the administration process, and omission as the most common
21 error in the dispensing process. In the "database name removed" database wrong quantity and wrong dose
22 are listed as two separate error categories. If the results within the administration process for these two
23 categories were combined, the total (n=243/1126, 22%) would exceed omitted medication, agreeing the
24 above findings by Storey et al.,²⁹ that an incorrect dose or quantity was the most frequent error category for
25 administration incident reports for PN in "Country Y" and "Country Z".

26 In this evaluation, quantitative analysis provided limited insight into PN components as contributory factors.
27 The complexity of PN and its ingredients are not captured within this data. Content analysis of the free-text

1 fields provided a more granular insight and revealed that specific ingredients such as intravenous ILEs, amino
2 acids, electrolytes, glucose and micronutrients were involved in PN-related incident reports. This resembles
3 the findings from previously discussed case reports and prevalence studies.^{17,23,27,29,31,32,46-48} Inadvertently
4 administering ILE at the rate of the non-lipid PN, and vice versa, in neonates and infants was a common
5 incident type seen in our study and literature.^{27,31,46,48} Other incident reports such as missing ingredients from
6 PN, using the wrong venous access and extravasation were also seen in our study and the literature. We
7 didn't see the varied severe outcomes as reported in the case reports, but these are published to highlight
8 fatal/rare outcomes.

9 An increase in the use of HPN has been reported in the "Country X".⁴⁹ This can be contributed to an increase
10 in cancer patients starting HPN to improve quality of life by preventing the consequences of malnutrition.^{49,50}
11 A large number of incident reports involving HPN were related to a recent national incident. In 2019 there
12 was disruption in HPN supply in "Country Y" and "Country Z" affecting over 500 patients.⁵¹ Content analysis
13 of incident reports described as moderate/severe harm and death in our study revealed this as a possible
14 contributory factor. Some patients on HPN who experienced incidents were admitted to hospital for
15 treatment, particularly when other co-morbidities were present. This suggested that organizational failures,
16 such as missed/delayed deliveries, when combined with high-risk groups such as those dependent of HPN,
17 can have disastrous effects. National incidents may be difficult to anticipate, however by highlighting high-
18 risk patients, harm could be minimised. A recent evaluation by a HPN multidisciplinary team demonstrated
19 interventions were recommended during 59.4% of follow-up assessments, and imperative to the ongoing
20 care of these complex patients.⁵² Murphy et al.⁵³ reported a case series of seven HPN incidents caused by
21 formulation mistakes, leading to hospitalization of one patient. Human error was the primary cause, and they
22 proposed prevention strategies such as integrated computerised systems, double-checking procedures and
23 open communication. There are limited publications regards patient safety incidents related to HPN in the
24 literature, and more are urgently required to understand risks, particularly in patients who are solely
25 dependent on HPN for their nutrients, fluid and electrolytes.

26 4.2. Strengths and limitations

27 The main strength of this study is its originality and scale. The "database name removed" database has been
28 used to evaluate medication incident reports, but not focussed on PN.^{54,55} This study also includes all patient

1 age groups, a time period sufficient to capture all relevant incident types, and an extensive search strategy
2 to capture as many PN-related incident reports as possible.

3 The limitations of this study are that only a sample of the low and no-harm incident reports were available
4 for analysis. We had to assume the sample we analyzed was representative of all PN-related incident reports.
5 Also, we did not analyze PN-related patient safety incident reports in non-medication incident categories.
6 Our data extraction process revealed that these incidents were reported in categories such as
7 treatment/procedure, however their analysis was not feasible for this Master's study. Therefore PN incidents
8 reported are likely to be an under-representation of the total number.

9 Drug searches of the "database name removed" system are conducted as free-form text using both generic
10 and brand names of medicines. This creates the need for extensive data cleaning due to the risk of incorrect
11 entries, and has previously been criticised by Cousins et al.⁵⁶ They suggested that medication names for all
12 incidents should be selected from a national database of medicines, such as the "organization removed"
13 Drugs and Devices list.⁵⁷ However, in the case of PN this is further complicated by the numerous components
14 contained in one bag, being mistaken for a food product by some healthcare professionals and not being
15 classified by the "organization removed" Drugs and Devices list.^{57,58}

16 The use of voluntary reporting methods from a local or national database to capture patient safety incidents
17 presents as a challenge as investigators have minimal control over the data reported. There is potential
18 reporter bias in the form of missing data, under-reporting and subjectivity on applying scales for level of
19 harm.⁵⁹ We have seen some of these issues in our study, where incident reports have been wrongly
20 categorized, data are missing or categorized as *other* for certain fields. We planned to analyze staff reporter
21 type however this field was rarely completed. Nevertheless, the data remains valuable in highlighting
22 medication incident reports and guiding the development of future research.^{54,60-62} Content analysis of free-
23 text data within the incident reports has shown to provide more meaningful results, and should be adopted
24 for future studies.

25 **4.3. Recommendations**

26 The future for minimizing patient safety incidents related to PN should be focussed on adding
27 systems/processes in the workplace to reduce risks. The low number of incident reports related to

1 moderate/severe harm or death is reassuring. 'Near misses' are incidents that have the potential to cause
2 harm but were prevented. These are not separately captured by the "database name removed" and could
3 be reported within the several thousand no/low harm incident reports. This study has provided an insight
4 into PN-related incidents and contributory factors for moderate/severe harm incidents and deaths. A similar
5 review of the no/low harm incidents could give an equally valuable insight and include near misses.

6 Administration was highlighted as the process with the highest number of incident reports, in all age groups
7 and all degrees of harm. Contributing factors such as young age, mistakes and venous access devices were
8 highlighted. These factors highlight the need for staff education and review of local standards/policies. Drug-
9 error reduction systems (DERS) and 'smart' infusion pumps have been introduced in healthcare to help
10 reduce drug errors by imposing dosing limits utilizing built-in drug libraries.⁶³ They aim to remove the
11 element of human error when setting up infusion pumps. Studies have demonstrated a reduction in
12 programming error rates but with the introduction of new error types e.g., overriding pump warnings and
13 out-dated drug libraries.⁶³⁻⁶⁷ A recent "organization removed"-funded review of infusion devices
14 recommended that advisory boards of relevant multi-professional organizations should develop validated
15 national drug libraries for smart infusion pumps.⁶⁸ This could be a positive step in the development of smart
16 pumps and their role in reducing programming errors for PN infusions.

17 The medication error categories seen in the dispensing process were omitted medication and wrong
18 quantity, some of which were related to transcribing errors. Several studies have investigated the impact of
19 computerized prescription tools on reducing errors related to PN, and this has been widely publicised in the
20 USA.^{6,69} In the "Country X" the uptake of electronic systems for prescribing medications such as intravenous
21 fluids and PN is low.⁷⁰ This is likely due to limitations of prescribing systems to include variations in infusion
22 rates, duration and volume for the range of intravenous infusions. The most effective tools have been
23 demonstrated to be those with integrated prescribing and compounding features as they remove the
24 transcribing process.⁷¹⁻⁷⁵ A national drive for quality improvement projects supporting integrated
25 computerised systems suitable for PN should be considered.

5. Conclusion

To our knowledge this study is the first national evaluation of PN-related incident reports in “Country Y” and “Country Z”. Consistent with previous non-“Country X”/local studies we demonstrated a low frequency of incident reports related to moderate or severe harm or death, that neonates are more susceptible to PN-related incidents and that incidents commonly occur during the administration process. We support the classification of PN as a high-risk medication, particularly in neonates and infants. Robust operational systems, including computerized tools should be introduced where possible to reduce errors. Patients dependent on HPN were identified as a high-risk group, requiring hospitalization, and reported a higher-than-expected degree of harm. Further investigations in this patient group are necessary. Near-miss incidents were not identified in this evaluation and content analysis of no/low harm incident reports may provide further insight. Limitations of voluntary reporting systems were recognized but the database was valued for the purpose of this study.

1 1 **References**

- 2
3 2 1. National Institute for Health and Care Excellence. Nutrition support for adults: oral nutrition
4
5 3 support, enteral tube feeding and parenteral nutrition. Clinical guideline [CG32].
6
7 4 <https://www.nice.org.uk/guidance/cg32>. Published 2006. Updated 2017. Accessed 18/04/2020.
8
9 5 2. World Health Organization. Medication Safety in High-risk Situations. Technical Report.
10
11 6 <https://apps.who.int/iris/bitstream/handle/10665/325131/WHO-UHC-SDS-2019.10-eng.pdf?ua=1>.
12
13 7 Published 2019. Accessed 11/11/2019.
14
15 8 3. Institute for Safe Medication Practices (ISMP). ISMP List of High-Alert Medications in Acute Care
16
17 9 Settings. Published 2018. Accessed 25/01/2023.
18
19 10 4. World Health Organization. Medication Safety in High-risk Situations. Technical Report.
20
21 11 <https://apps.who.int/iris/bitstream/handle/10665/325131/WHO-UHC-SDS-2019.10-eng.pdf?ua=1>.
22
23 12 Published 2019. Accessed 05/09/2021.
24
25 13 5. Mirtallo JM. Consensus of parenteral nutrition safety issues and recommendations. *J Parenter*
26
27 14 *Enteral Nutr.* 2012;36(2 Suppl):62S.
28
29 15 6. Ayers P, Adams S, Boullata J, et al. A.S.P.E.N. parenteral nutrition safety consensus
30
31 16 recommendations. *J Parenter Enteral Nutr.* 2014;38(3):296-333.
32
33 17 7. Boullata JI, Guenter P, Mirtallo JM. A parenteral nutrition use survey with gap analysis. *J Parenter*
34
35 18 *Enteral Nutr.* 2013;37(2):212-222.
36
37 19 8. White R. Quality parenteral nutrition: an ideal mixed bag. *Proc Nutr Soc.* 2011;70(3):285-292.
38
39 20 9. NHS England. Patient Safety Alert. Stage Three: Directive Improving medication error incident
40
41 21 reporting and learning. [https://www.england.nhs.uk/wp-content/uploads/2014/03/psa-sup-info-](https://www.england.nhs.uk/wp-content/uploads/2014/03/psa-sup-info-med-error.pdf)
42
43 22 [med-error.pdf](https://www.england.nhs.uk/wp-content/uploads/2014/03/psa-sup-info-med-error.pdf). Published 2014. Accessed 18/02/2020.
44
45 23 10. Mistry P, Smith RH, Fox A. Patient Safety Incidents Related to the Use of Parenteral Nutrition in All
46
47 24 Patient Groups: A Systematic Scoping Review. *Drug Saf.* 2021.
48
49 25 11. Habsah H, Zeehaida M, Van Rostenberghe H, et al. An outbreak of *Pantoea* spp. in a neonatal
50
51 26 intensive care unit secondary to contaminated parenteral nutrition. *J Hosp Infect.* 2005;61(3):213-
52
53 27 218.
54
55
56
57
58
59
60

- 1 12. Maltezou HC, Tryfinopoulou K, Katerelos P, et al. Consecutive *Serratia marcescens* multiclone
2 outbreaks in a neonatal intensive care unit. *Am J Infect Control*. 2012;40(7):637-642.
3
- 4 13. Staes C, Jacobs J, Mayer J, Allen J. Description of outbreaks of health-care-associated infections
5 related to compounding pharmacies, 2000-12. *Am J Health Syst Pharm*. 2013;70(15):1301-1312.
6
- 7 14. Tresoldi AT, Padoveze MC, Trabasso P, et al. Enterobacter cloacae sepsis outbreak in a newborn
8 unit caused by contaminated total parenteral nutrition solution. *Am J Infect Control*.
9 2000;28(3):258-261.
10
- 11 15. Al Nemri AM, Ignacio LC, Al Zamil FA, Al Jarallah AS. Rare but fatal complication of umbilical venous
12 catheterization. *Congenit Heart Dis*. 2006;1(4):180-183.
13
- 14 16. Booth SA, Norton B, Mulvey DA. Central venous catheterization and fatal cardiac tamponade. *Br J*
15 *Anaesth*. 2001;87(2):298-302.
16
- 17 17. Cheah FC, Boo NY, Latif JY. An unusual case of refractory hypoglycaemia in a neonate receiving total
18 parenteral nutrition. *Acta Paediatr*. 2000;89(4):497-498.
19
- 20 18. Pegu S, Murthy P. Ascites with hepatic extravasation of total parenteral nutrition (TPN) secondary
21 to umbilical venous catheter (UVC) malposition in an extremely preterm baby. *BMJ Case Reports*.
22 2018;2018.
23
- 24 19. Zasada IA, Banner J, Bugge A. "Nutrition or no nutrition?": Chylothorax or leakage of total
25 parenteral nutrition? *Forensic Sci Med Pathol*. 2019;15(3):470-473.
26
- 27 20. Cohen MR. Ensure Proper Mixing of Dual-Chamber Bags; Do Recruiters and Telemarketers
28 Contribute to Dispensing Errors?; Wrong Dose Recognized, Not Returned, and Eventually
29 Administered; Pediatric Medication Error Prevention Guidelines Published by ISMP and PPAG;
30 Nonproprietary Names Also Involved in Errors. *Hosp Pharm*. 2002;37(9):911-1000.
31
- 32 21. Adams A, Wegner E. The effect of total parenteral nutrition (TPN) on glomerular filtration rate
33 (GFR) measurement. *Internal Med J*. 2011;41(3):23.
34
- 35 22. Fairholm L, Saqui O, Baun M, et al. Monitoring parenteral nutrition in hospitalized patients: issues
36 related to spurious bloodwork. *Nutr Clin Pract*. 2011;26(6):700-707.
37
- 38 23. Cohen MR, Smetzer JL. Another Tragic Parenteral Nutrition Compounding Error: Change in Anzemet
39 Indication: Teva's Lansoprazole Orally Disintegrating Tablet Clogs Tubes: Lawyers Weigh in on
40 Consistent Use of Smart Pump Libraries. *Hosp Pharm*. 2011;46(7):470-476.
41

- 1 24. Grissinger M. "Smart" infusion pumps join CPOE and bar coding as way to prevent medication
2 errors. *P and T*. 2006;31(10):562.
3
- 4 25. Lodeserto F, Al-Jaghbeer M, Huang D. Accidental Bolus of Parenteral Nutrition. *J Parenter Enteral*
5 *Nutr*. 2016;40(6):883-885.
6
- 7 26. Ali A, Walentik C, Mantych GJ, et al. Iatrogenic acute hypermagnesemia after total parenteral
8 nutrition infusion mimicking septic shock syndrome: two case reports. *Pediatr*. 2003;112(1):e70-72.
9
- 10 27. Bora KM, Hedge MW. Neonatal triglyceride levels after massive lipid bolus - Implications for lipid
11 rescue. *Clin Toxicol*. 2009;47(7):760.
12
- 13 28. Low E, Ryan CA. Overdose of Intravenous Intralipid in a Premature Neonate. *Jt Comm J Qual Patient*
14 *Saf*. 2007;33(10):588-589.
15
- 16 29. Storey MA, Weber RJ, Besco K, et al. Evaluation of Parenteral Nutrition Errors in an Era of Drug
17 Shortages. *Nutr Clin Pract*. 2016;31(2):211-217.
18
- 19 30. Snijders C, van Lingen RA, Klip H, et al. Specialty-based, voluntary incident reporting in neonatal
20 intensive care: description of 4846 incident reports. *Arch Dis Child Fetal Neonatal Ed*.
21 2009;94(3):F210-215.
22
- 23 31. Sacks GS, Rough S, Kudsk KA. Frequency and severity of harm of medication errors related to the
24 parenteral nutrition process in a large university teaching hospital. *Pharmacother*. 2009;29(8):966-
25 974.
26
- 27 32. Narula P, Hartigan D, Puntis JWL. The frequency and importance of reported errors related to
28 parenteral nutrition in a regional paediatric centre. *E Spen Eur E J Clin Nutr Metab*. 2011;6:e131-
29 e134.
30
- 31 33. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for
32 conducting a qualitative descriptive study. *Nurs Health Sci*. 2013;15(3):398-405.
33
- 34 34. Saldana J. An Introduction to Codes and Coding. In: Saldana J, ed. *The Coding Manual for*
35 *Qualitative Researchers*. 1st ed. London: Sage Publications Ltd; 2009:1-31.
36
- 37 35. Vaismoradi M, Jones J, Turunen H, Snelgrove S. Theme development in qualitative content analysis
38 and thematic analysis. *J Nurs Educ Pract*. 2016;6:100.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 36. Information Commissioner's Office. Guide to the General Data Protection Regulation (GDPR).
2 [https://ico.org.uk/media/for-organisations/guide-to-data-protection/guide-to-the-general-data-
4 protection-regulation-gdpr-1-0.pdf](https://ico.org.uk/media/for-organisations/guide-to-data-protection/guide-to-the-general-data-
3 protection-regulation-gdpr-1-0.pdf). Published 2019. Accessed 29/01/2020.
5
6
7 37. National Coordinating Council for Medication Error Reporting and Prevention. Index for
8
9 38. National Coordinating Council for Medication Error Reporting and Prevention. Index for
10
11 39. Categorizing Medication Errors. [https://www.nccmerp.org/sites/default/files/indexColor2001-06-
13 12.pdf](https://www.nccmerp.org/sites/default/files/indexColor2001-06-
12 12.pdf). Published 2001. Accessed 11/11/2019.
14
15 40. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric
16
17 inpatients. *JAMA*. 2001;285(16):2114-2120.
18
19 41. Cowley E, Williams R, Cousins D. Medication errors in children: a descriptive summary of
20
21 medication error reports submitted to the United States pharmacopeia. *Curr Ther Res Clin Exp*.
22
23 2001;62(9):627-640.
24
25 42. Beaney AM. *Quality Assurance of Aseptic Preparation Services: Standards Handbook*. 5th ed.
26
27 London, UK: Pharmaceutical Press; 2016.
28
29 43. Jandot E, Savelli M, Pinte G, et al. Supplementations of industrial multichamber parenteral nutrition
30
31 bags in critically ill children: Safety of the practice. *Nutrition in Clinical Practice*. n/a(n/a).
32
33 44. Colomb V, Marlowe ML, Bonnot D, Rigo J. Practical use of a new three-chamber bag for parenteral
34
35 nutrition in pediatric patients. *e-SPEN Journal*. 2012;7(2):e93-e99.
36
37 45. Rigo J, Marlowe ML, Bonnot D, et al. Benefits of a New Pediatric Triple-Chamber Bag for Parenteral
38
39 Nutrition in Preterm Infants. *J Pediatr Gastroenterol Nutr*. 2012;54(2):210-217.
40
41 46. Bateman R, Donyai P. Errors associated with the preparation of aseptic products in UK hospital
42
43 pharmacies: lessons from the national aseptic error reporting scheme. *Qual Safety Health Care*.
44
45 2010;19(5):e29.
46
47 47. British Association of Perinatal Medicine. Use of Central Venous Catheters in Neonates (Revised
48
49 2018), A BAPM Framework for Practice. [https://www.bapm.org/resources/10-use-of-central-
51 venous-catheters-in-neonates-revised-2018](https://www.bapm.org/resources/10-use-of-central-
50 venous-catheters-in-neonates-revised-2018). Published 2015. Accessed 13/09/2021.
52
53 48. Cole C, Robertson S. Nine cases of unintentional rapid infusion of lipid emulsion in children: root
54
55 cause analysis and changes to practice. *Arch Dis Child*. 2014;99:e3.
56
57 49. Grissinger M. A fatal zinc overdose in a neonate: confusion of micrograms with milligrams. *P and T*.
58
59 2011;36(7):393-409.
60

- 1 48. Hicks RW, Becker SC, Chuo J. A summary of NICU fat emulsion medication errors and nursing
2 services: data from MEDMARX. *Adv Neonatal Care*. 2007;7(6):299-308.
- 3
4 49. British Artificial Nutrition Survey (BANS). Artificial Nutrition Support in the UK 2005-2015, Adult
5 Home Parenteral Nutrition & Home Intravenous Fluids.
6
7
8
9 5 <https://www.bapen.org.uk/images/pdfs/reports/bans-report-2016.pdf>. Published 2016. Accessed
10
11 6 19/09/2021.
- 12
13 7 50. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer.
14
15
16 8 *Clin Nutr*. 2021;40(5):2898-2913.
- 17
18 9 51. The Lancet Gastroenterology Hepatology. NHS England faces emergency in parenteral nutrition
19 supplies. *Lancet Gastroenterol Hepatol*. 2019;4(10):743.
- 20
21
22 11 52. Kinnaire K, Monczka J, Butt J. Parenteral Nutrition Clinical Interventions Made by a Home Infusion
23 Nutrition Support Team. *J Parenter Enteral Nutr*. 2021;45:S65-67.
- 24
25 12
26
27 13 53. Murphy MK, Gura KM, Tascione C, et al. Home Parenteral Nutrition and Intravenous Fluid Errors
28 Discovered Through Novel Clinical Practice of Reconciling Compounding Records: A Case Series.
29
30
31 15 *Nutr Clin Pract*. 2017;32(6):820-825.
- 32
33
34 16 54. Harkanen M, Vehvilainen-Julkunen K, Murrells T, Rafferty AM, Franklin BD. Medication
35 administration errors and mortality: Incidents reported in England and Wales between 2007 2016.
36
37
38 18 *Res Social Admin Pharm*. 2019;15(7):858-863.
- 39
40 19 55. Stuttaford L, Chakraborty M, Carson-Stevens A, Powell C. Patient safety incidents in neonatology: a
41 10-year descriptive analysis of reports from NHS England and Wales. *Arch Dis Child*. 2018;103(Suppl
42 1):A78.
- 43
44
45 21
46
47 22 56. Cousins DH, Gerrett D, Warner B. A review of medication incidents reported to the National
48 Reporting and Learning System in England and Wales over 6 years (2005-2010). *Br J Clin Pharmacol*.
49
50
51 24 2011;74:597-604.
- 52
53
54 25 57. NHS Business Services Authority. Dictionary of medicines and devices (dm+d).
55
56 26 [https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd)
57
58 27 [medicines-and-devices-dmd](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd). Accessed 18 Feb 2020.
- 59
60 28 58. Guenter P, Ayers P, Boullata JI, et al. Parenteral Nutrition Errors and Potential Errors Reported Over
29 the Past 10 Years. *Nutr Clin Pract*. 2017;32(6):826-830.

- 1 59. Williams SD, Ashcroft DM. Medication errors: how reliable are the severity ratings reported to the
2 national reporting and learning system? *Int J Qual Health Care*. 2009;21(5):316-320.
3
4 60. Rees P, Edwards A, Powell C, et al. Pediatric immunization-related safety incidents in primary care:
5 A mixed methods analysis of a national database. *Vaccine*. 2015;33(32):3873-3880.
6
7 61. Catchpole K, Bell MDD, Johnson S. Safety in anaesthesia: a study of 12 606 reported incidents from
8 the UK National Reporting and Learning System. *Anaesthesia*. 2008;63(4):340-346.
9
10 62. MacLennan AI, Smith AF. An analysis of critical incidents relevant to pediatric anesthesia reported
11 to the UK National Reporting and Learning System, 2006–2008. *Paediatr Anaesth*. 2011;21(8):841-
12 847.
13
14 63. Ohashi K, Dalleur O, Dykes PC, Bates DW. Benefits and risks of using smart pumps to reduce
15 medication error rates: a systematic review. *Drug Saf*. 2014;37(12):1011-1020.
16
17 64. Schnock KO, Dykes PC, Albert J, et al. The frequency of intravenous medication administration
18 errors related to smart infusion pumps: a multihospital observational study. *BMJ Qual Saf*.
19 2017;26(2):131-140.
20
21 65. Lyons I, Furniss D, Blandford A, et al. Errors and discrepancies in the administration of intravenous
22 infusions: a mixed methods multihospital observational study. *BMJ Qual Saf*. 2018;27(11):892-901.
23
24 66. Hsu KY, DeLaurentis P, Bitan Y, Degnan DD, Yih Y. Unintended Patient Safety Risks Due to Wireless
25 Smart Infusion Pump Library Update Delays. *J Patient Saf*. 2019;15(1):e8-e14.
26
27 67. Melton KR, Timmons K, Walsh KE, Meinzen-Derr JK, Kirkendall ES. Smart pumps improve
28 medication safety but increase alert burden in neonatal care. *BMC Med Inform Decis Mak*.
29 2019;19(1):213.
30
31 68. Healthcare Safety Investigation Branch. Summary report. Procurement, usability and adoption of
32 'smart' infusion pumps. [https://hsib-kqcco125-
33 media.s3.amazonaws.com/assets/documents/HSIB_Procurement_usability_and_adoption_of_sma
34 rt_infusion_pumps_Summary.pdf](https://hsib-kqcco125-media.s3.amazonaws.com/assets/documents/HSIB_Procurement_usability_and_adoption_of_smart_infusion_pumps_Summary.pdf). Published 2020. Accessed 06/09/2021.
35
36 69. Vanek VW, Ayers P, Kraft M, et al. A Call to Action for Optimizing the Electronic Health Record in
37 the Parenteral Nutrition Workflow. *Nutr Clin Pract*. 2018;33(5):e1-e21.
38
39 70. Ahmed Z, Garfield S, Jani Y, Jheeta S, Franklin BD. Impact of electronic prescribing on patient safety
40 in hospitals: implications for the UK. *Clinical Pharmacist*. 2016;8(5).
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 71. Brown CL, Garrison NA, Hutchison AA. Error reduction when prescribing neonatal parenteral
2 nutrition. *Am J Perinatol*. 2007;24(7):417-427.
3
4 72. Crews J, Rueda-de-Leon E, Remus D, et al. Total Parenteral Nutrition Standardization and Electronic
5 Ordering to Reduce Errors: a Quality Improvement Initiative. *Pediatr Qual Saf*. 2018;3(4):e093.
6
7 73. Hilmas E, Partyka CM. Implementation of computerized parenteral nutrition orders in a community
8 pediatric hospital. *Am J Health Syst Pharm*. 2004;61(3):273-277.
9
10 74. Huston RK, Markell AM, McCulley EA, Marcus MJ, Cohen HS. Computer programming: quality and
11 safety for neonatal parenteral nutrition orders. *Nutr Clin Pract*. 2013;28(4):515-521.
12
13 75. Lehmann CU, Conner KG, Cox JM. Preventing provider errors: online total parenteral nutrition
14 calculator. *Pediatr*. 2004;113(4):748-753.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Tables**2 **Table 1. Patient characteristics of all PN-related incident reports by reported harm**

	Frequency of incident reports within each reported degree of harm [¶]					
	No harm	Low	Moderate	Severe	Death	Total (%)
Patient age[¶]						
<28 days	495	62	10	2	1	570 (25)
1 month- 1 yr.	344	45	8	0	0	397 (18)
2-4 yrs.	60	8	0	0	0	68 (3)
5-11 yrs.	90	11	2	0	0	103 (5)
12-17 yrs.	51	5	1	0	1	58 (3)
18-25 yrs.	19	8	1	0	0	28 (1)
26-35 yrs.	30	9	1	1	0	41 (2)
36-45 yrs.	43	12	0	0	1	56 (2)
46-55 yrs.	85	20	1	0	0	106 (5)
56-65 yrs.	101	32	9	0	0	142 (6)
66-75 yrs.	146	26	4	0	0	176 (8)
76-85 yrs.	110	26	3	0	0	139 (6)
>85 yrs.	27	10	2	0	0	39 (2)
Total (missing data for 319 entries)	1601	274	42	3	3	1923 (100)
Location[¶]						
Inpatient	1507	242	28	2	1	1780 (79)
Support services	222	35	6	0	1	264 (12)
Other	110	19	3	0	0	132 (6)
General areas	25	4	2	0	0	31 (1)
Private house/flat etc	5	6	6	1	1	19 (1)
Day case services	3	1	0	0	0	4 (0)
Outpatient dept	2	2	0	0	0	4 (0)
Accident, minor injuries, medical assessment unit	0	0	1	0	0	1 (0)
In vehicle/in transit	1	0	0	0	0	1 (0)
Total (missing data for 6 entries)	1875	309	46	3	3	2236 (100)
Speciality[¶]						
Medical specialities	643	83	12	3	2	743 (33)
Other Specialities	354	53	9	0	0	416 (19)
Surgical specialities	259	70	11	1	1	342 (15)
Other	286	41	6	0	0	333 (15)
Children's specialities	177	26	7	0	0	210 (9)
Anaesthesia, Pain, Critical Care	64	14	1	0	0	79 (4)
Not applicable	39	11	0	0	0	50 (2)
Obstetrics & Gynaecology	23	8	0	0	0	31 (1)
Diagnostic Services	12	0	0	0	0	12 (1)
Unknown	9	2	0	0	0	11 (0)
Learning disabilities	8	0	1	0	0	9 (0)
Primary Care/Community	3	1	0	0	0	4 (0)
Accident & Emergency	2	0	0	0	0	2 (0)
Total	1879	309	47	4	3	2242 (100)

3 Note: [¶]sub-categories as set within "database name removed" database
 4

Table 2. Medication incident characteristics of all PN-related incident reports by reported harm

Medication Process [¶]	Frequency of incident reports within each reported degree of harm [¶]					Total (%)
	No harm	Low	Moderate	Severe	Death	
Administration/Preparation in Clinical Area	914	184	22	4	2	1126 (50)
Preparation from all locations/Dispensing from Pharmacy	433	54	6	0	0	493 (22)
Prescribing	273	27	4	0	1	305 (14)
Other	184	29	9	0	0	222 (10)
Monitoring	63	14	4	0	0	81 (4)
Supply or use of OTC medicines	7	1	1	0	0	9 (0)
Advice	5	0	1	0	0	6 (0)
Total	1879	309	47	4	3	2242 (100)
Medication Error Category[¶]						
Other	497	73	20	0	1	591 (26)
Omitted medication/ingredient	212	65	11	2	1	291 (13)
Wrong quantity	183	29	1	0	1	214 (10)
Wrong/unclear dose or strength	175	25	4	1	0	205 (9)
Wrong drug/medicine	155	11	0	0	0	166 (7)
Wrong frequency	113	23	1	0	0	137 (6)
Wrong method of preparation/supply	96	17	0	0	0	113 (5)
Wrong/omitted/passed expiry	87	8	0	0	0	95 (4)
Wrong formulation	81	7	2	0	0	90 (4)
Wrong/ transposed/omitted medicine label	72	8	0	0	0	80 (4)
Wrong route	54	13	2	0	0	69 (3)
Mismatching between patient and medicine	62	6	1	0	0	69 (3)
Unknown	33	6	1	0	0	40 (2)
Wrong Storage	26	4	0	0	0	30 (1)
ADR- with use as intended	2	14	3	1	0	20 (1)
Contraindication in relation to drug/ condition	18	0	1	0	0	19 (1)
Wrong/omitted verbal patient directions	7	0	0	0	0	7 (0)
Wrong/omitted PIL	4	0	0	0	0	4 (0)
Patient allergic to treatment	2	0	0	0	0	2 (0)
Total	1879	309	47	4	3	2242 (100)

Note: [¶]sub-categories as set within "database name removed" database

Abbreviations: ADR: adverse drug reaction; OTC: over-the-counter; PIL: patient information leaflet

Table 3. Frequency of PN-related incident reports in each age group by medication process

Medication process [¶]	Frequency of incident reports in each age group (%)		
	Children (0-17 yrs.)	Adults (≥18 yrs.)	Total
Administration/Preparation in Clinical Area	623 (52)	379 (52)	1002 (52)
Preparation from all locations/Dispensing from Pharmacy	221 (18)	180 (25)	401 (21)
Prescribing	180 (15)	83 (11)	263 (14)
Other	110 (9)	62 (9)	172 (9)
Monitoring	59 (5)	13 (2)	72 (4)
Supply or use of OTC medicines	1 (0)	6 (1)	7 (0)
Advice	3 (0)	3 (0)	6 (0)
Total	1197 (100)	726 (100)	1923* (100)

Note: [¶]sub-categories as set within "database name removed" database; *missing data for 319 entries

Abbreviations: OTC: over-the-counter

For Peer Review

Table 4. Frequency of PN-related incident reports in each medication process by medication error category

Medication Error Category [¶]	Frequency of incident reports in each medication process [¶] (%)							Total
	Prescribing	Preparation from all locations/Dispensing from Pharmacy	Supply or use of OTC medicines	Administration/Preparation in Clinical Area	Monitoring	Advice	Other	
Other	63 (21)	98 (20)	3 (33)	257 (23)	30 (37)	5 (83)	135 (61)	591 (26)
Omitted medication/ingredient	25 (8)	96 (19)	3 (33)	142 (13)	5 (6)	0 (0)	20 (9)	291 (13)
Wrong quantity	38 (12)	17 (3)	0 (0)	137 (12)	8 (10)	0 (0)	14 (6)	214 (10)
Wrong/unclear dose or strength	67 (22)	28 (6)	0 (0)	106 (9)	2 (2)	1 (17)	1 (0)	205 (9)
Wrong drug/medicine	33 (11)	38 (8)	0 (0)	89 (8)	1 (1)	0 (0)	5 (2)	166 (7)
Wrong frequency	21 (7)	3 (1)	0 (0)	104 (9)	6 (7)	0 (0)	3 (1)	137 (6)
Wrong method of preparation/supply	8 (3)	43 (9)	1 (11)	52 (5)	3 (4)	0 (0)	6 (3)	113 (5)
Wrong/omitted/passed expiry	2 (1)	21 (4)	0 (0)	52 (5)	12 (15)	0 (0)	8 (4)	95 (4)
Wrong formulation	18 (6)	33 (7)	0 (0)	34 (3)	0 (0)	0 (0)	5 (2)	90 (4)
Wrong/transposed/omitted medicine label	2 (1)	69 (14)	0 (0)	9 (1)	0 (0)	0 (0)	0 (0)	80 (4)
Wrong route	7 (2)	2 (2)	0 (0)	55 (5)	2 (2)	0 (0)	3 (1)	69 (3)
Mismatching between patient and medicine	11 (4)	27 (5)	0 (0)	28 (2)	0 (0)	0 (0)	3 (1)	69 (3)
Unknown	5 (2)	6 (1)	2 (22)	14 (1)	5 (6)	0 (0)	8 (4)	40 (2)
Wrong Storage	0 (0)	5 (1)	0 (0)	17 (2)	1 (1)	0 (0)	7 (3)	30 (1)
ADR- with use as intended	1 (0)	0 (0)	0 (0)	15 (1)	4 (5)	0 (0)	0 (0)	20 (1)
Contraindication in relation to drug/condition	3 (1)	4 (1)	0 (0)	10 (1)	1 (1)	0 (0)	1 (0)	19 (1)
Wrong/Omitted verbal patient directions	1 (0)	1 (0)	0 (0)	4 (0)	0 (0)	0 (0)	1 (0)	7 (0)
Wrong/omitted PIL	0 (0)	2 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (0)	4 (0)
Patient allergic to treatment	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	2 (0)
Total	305 (100)	493 (100)	9 (100)	1126 (100)	81 (100)	6 (100)	222 (100)	2242 (100)

Note: [¶]sub-categories as set within "database name removed" database
 Abbreviations: ADR: adverse drug reaction; OTC: over-the-counter; PIL: patient information leaflet

Table 5. Frequency of incidents type described in the free-text for moderate/severe harm and death incident reports

Incidents- themes and codes	Frequency	%
1. Clinical treatment decision-making error	2	4%
2. Medication not commenced in a timely fashion	1	2%
3. Medication unavailable- parenteral nutrition	3	6%
4. Prescribing medication incident	4	8%
4.1 Medication not prescribed	1	2%
4.2 Wrong strength	1	2%
4.3 Inappropriately prescribed/not stopped (insulin)	1	2%
4.4 Unsafe medication prescribed	1	2%
5. Dispensing/compounding/delivery medication incident	16	30%
5.1 Inappropriate medication	2	4%
5.2 Medication not delivered	4	8%
5.3 Medication damaged	1	2%
5.4 Wrong formulation	3	6%
5.5 Medication not dispensed	6	11%
6. Administering medications incident	24	45%
6.1 Wrong dose administered	8	15%
6.2 Medication not administered	2	4%
6.3 Wrong route administered	1	2%
6.4 Adverse event from medication administration	13	25%
7. Monitoring medication incident	2	4%
7.1 Inappropriate interpretation of result leading to mis-dosing (insulin)	1	2%
7.2 Medication dose (insulin) not adjusted, when appropriate	1	2%
8. Incorrect medication storage	1	2%
Total	53	100%

Table 6. Frequency of contributory factors described in the free-text for moderate/severe harm and death incident reports (Note, some incident reports described more than one contributory factor)

Contributory factors- themes and codes	Frequency	%
1. Patient factors (Total)	(37)	42%
1.1 Patient age		
1.1.1 Infant <1 year	11	12%
1.2 Behaviour of patients/family		
1.2.1 Patient did not follow healthcare professional advice	1	1%
1.3 Pathophysiological factors		
1.3.1 Drug interaction with parenteral nutrition	1	1%
1.3.2 Co-morbidity - the presence of one or more additional diseases	8	9%
1.3.3 Failed treatment- no venous access	1	1%
1.3.4 Patient dependent on home parenteral nutrition	14	16%
1.3.5 Having parenteral nutrition	1	1%
2. Staff factors (Total)	(14)	16%
2.1 Task-a piece of work to be done or undertaken.		
2.1.1 Failure to follow protocol, procedures or regulation	2	2%
2.1.2 Inadequate skill set/knowledge	1	1%
2.1.3 Task not carried out/incomplete/inadequate	2	2%
2.2 Cognitive factors		
2.2.1 Mistake	9	10%
3. Equipment (Total)	(10)	11%
3.1 Lack of stock- parenteral nutrition	3	3%
3.2 Infusion pump device		
3.2.1 Pump unavailable	1	1%
3.2.2 Pump failure	1	1%
3.3 Venous access device		
3.3.1 Three-way tap	1	1%
3.3.2 Related to device used	4	4%
4. Organization (Total)	(28)	31%
4.1 Working conditions		
4.1.1 Staffing levels- provision of healthcare staff	1	1%
4.2 Protocols/Policies/Standards/Guidelines inadequate, absent or not available		
4.2.1 Procurement procedures	2	2%
4.2.2 Dispensing protocols inadequate/inefficient	2	2%
4.2.3 Infection control protocol	1	1%
4.3 External company/manufacturer		
4.3.1 Service failure due to miscommunication	2	2%
4.3.2 Service failure due to finance issue	1	1%
4.3.3 Service failure due to national incident	9	10%
4.3.4 Service failure due to internal error	2	2%
4.4 Continuity of care between different providers		
4.4.1 Locum/agency staff	3	3%
4.5 Education & Training		
4.5.1 Knowledge of others' roles	1	1%
4.5.2 Other training needs identified	2	2%
4.6 Service Unavailable		
4.6.1 Lack of/insufficient compounding facilities	2	2%
Total	89	100%


Figures


Figure 1. Screening process of PN-related incident reports from the “database name removed” database

Figure 2. Breakdown of all PN-related incident reports by patient age groups

Figure 3. Diagram displaying outcomes of incident reports related to moderate/severe harm or death from the content analysis. *(Note, some incident reports described more than one outcome)*

For Peer Review






Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplementary material

Table S1. NRLS Search Strategy and Sampling Method

Date Range: Incidents reported to have occurred between 01 April 2015 and 31 March 2020 and reported to the NRLS on or before 16 April 2021.

Categorical Criteria: Type of Incident IS EQUAL TO: Medication

Free-text filters: **All terms searched in the following fields:**

A. BROAD NAME SEARCH:

1. Description of what happened
2. Actions Preventing Reoccurrence
3. Apparent Causes
4. Location - Free-text
5. Approved Drug Name (Drug 1)
6. Approved Drug Name (Drug 2)

B. BRAND NAME SEARCH:

1. Description of what happened
2. Actions Preventing Reoccurrence
3. Apparent Causes
4. Approved Drug Name (Drug 1)
5. Approved Drug Name (Drug 2)

A. Free-text BROAD NAME search terms based the following terms (including misspellings and variations):

Free-text Search: PN OR HPN OR TPN OR parenteral nutrition

B. Free-text BRAND NAME search terms based the following terms (including misspellings and variations, all separated by 'OR'):

Aminolect	Intralipid	Omegaven
Aminomix	Kabiven	Primene
Aminoplasma	Lipodem	SMOFkabiven
Aminoven	Lipoflex	SMOFlipid
Babiven	Lipofundin	SMOFven
Clinimix	Numeta	Synthamin
ClinOleic	Nutriflex	Triomel
Finomel	Omeflex	Vamin
		Vitrimix

Sampling: Dataset provided by NRLS included all output from search "**A AND B**", and a random sample of output from search "**A OR B**". All incidents resulting in moderate/severe harm or death from both searches were supplied.

Table S2. NRLS fields used in data analysis

Data field	In this study fields used in...	
	Quantitative analysis	Content analysis
incident ID	no	no
Care Setting of Occurrence	yes	no
Location (lv1)	no	no
Location (lv2)	yes	no
Location (lv3)	no	no
Location - Free-text	no	no
Incident Category - Lvl1	no	no
Incident Category - Lvl2	no	no
Incident Category - Free-text	no	no
Description of what happened	no	yes
Actions Preventing Reoccurrence	no	yes
Apparent Causes	no	yes
Patient Age Range	yes	no
Specialty - Lvl 1	yes	no
Specialty - Lvl 2	no	no
Specialty - Free-text	no	no
Reported Degree of Harm	yes	no
Med Process	yes	no
Med Error Category	yes	no
Approved Name (Drug 1)	no	no
Proprietary Name (Drug 1)	no	no
Route (Drug 1)	no	no
Type of Device	no	no
Date incident received by NRLS	no	no
Current location of device	no	no
Device name	no	no
Manufacturer	no	no
Supplier	no	no
Approved Name (Drug 2)	no	no
Proprietary Name (Drug 2)	no	no
Year of Occurrence	yes	no
Month of Occurrence	no	no
Type of device - free-text	no	no
termfound	no	no
TriggerCode_Found_In	no	no
Staff Reporter type	yes	no